The COVID-19 pandemic had negative consequences on the mental health of the general population; especially generalized anxiety disorder, whose post-pandemic prevalence increased by 25% (1). Clinically, GAD is expressed through excessive worry (anxious anticipation) about various events or activities. The intensity, duration, or frequency of GAD is often disproportionate to the actual likelihood or impact of an event (2).

Scientific evidence indicates that this disorder is closely linked to intense and difficult-to-manage stress situations. In many cases, worsening anxiety can lead to the onset of depressive symptoms (3); representing a clear indicator of psychological distress (4), with negative effects on both mental and physical health, and a direct impact on daily activities (5).

Additionally, anxiety often coexists with other disorders, such as depression, sleep disorders (6), and suicidal ideation (7, 8), acting as a trigger for multiple diseases (9, 10). This comorbidity not only intensifies anxiety symptoms but also prolongs their duration and reduces the effectiveness of interventions (11). Therefore, early detection is essential to mitigate its impact on mental health and develop prevention and treatment plans that minimize the occurrence of associated pathologies (12), alleviating the burden on the individual and facilitating recovery (3).

An economical, valid, and reliable way to detect GAD is through rapid tests. The Generalized Anxiety Disorder Test (GAD-7) (13), is a self-administered clinical scale used to assess generalized anxiety disorder over the past two weeks, according to DSM-V criteria (2). It is an instrument that is easy to apply, score, and interpret, with widespread use in hospital systems and strong support in the medical literature (14, 15).

The GAD-7 has demonstrated good clinical utility and excellent psychometric properties for quickly assessing GAD symptoms in international studies, showing adequate internal consistency (Cronbach’s Alpha >.70) (16, 17). During the COVID-19 pandemic, its use expanded to numerous studies worldwide (18–20). In Latin America and the Caribbean (LAC), it has also been applied, showing robust validity and reliability indicators (15, 21).

However, to date, no studies have provided evidence of the GAD-7’s invariance based on demographic characteristics in this region. This information is essential as it would strengthen the instrument’s validity for use in diverse populations within LAC. Therefore, the objective of this study was to evaluate the factorial invariance of the Generalized Anxiety Disorder Test considering gender and country of residence in a large sample of adults from the region.

In Table 2 , the descriptive statistics for the seven items of GAD are shown. It can be observed that item 5 has the lowest mean value, while item 3 has the highest mean value. Regarding Skewness and Kurtosis, these are close to zero, indicating that the data distribution is unlikely to affect subsequent analyses.

Next, confirmatory factor analysis was conducted to study the internal structure of the GAD-7. The models analyzed and their fit indices are presented in Table 3 . For the instrument, the unidimensional structure without correlated errors showed a good fit in the CFI, TLI, and SRMR indices. However, the RMSEA index indicated an inadequate fit; therefore, the model was re-specified by adding the covariance between item 1 and item 2, which reduced the RMSEA value, indicating an adequate fit (<.08) to the model. Moreover, a theoretical explanation is that GAD-7 items 1 and 2 measure closely related constructs within the domain of generalized anxiety. Item 1 (“Feeling nervous, anxious, or on edge”) and item 2 (“Not being able to stop or control worrying/disquiet”) reflect a common core of anxiety-related emotional arousal and intrusive thoughts (32). Both items target the core of generalized anxiety disorder, which is characterized primarily by excessive worry and difficulties in controlling those thoughts (33). Therefore, it is expected that they share a considerable portion of common variance, which explains the need to model this covariance.

Figure 1 presents the factor loadings of the model that showed the best fit for the GAD. In this case, the factor loadings were greater than.71, and the correlated error between item 1 and item 2 had a value of.31.

Subsequently, the invariance of the GAD-7 measures was evaluated according to gender and country. As shown in Table 4 , the invariance analysis reveals that the factor structure of the GAD-7 by gender showed fit indices ranging from adequate to good at the configural, threshold, metric, scalar, and strict levels. Additionally, the differences between the fit indices were smaller than the value established in the data analysis section, indicating that the factor structure of the instrument presents measurement invariance and is equivalent for both groups (men and women). The same results were observed when using the country as the comparison variable. It was found that the structure (configural), thresholds, factor loadings (metric), intercepts (scalar), and residuals (strict) were equivalent between the group.

Finally, McDonald’s Omega coefficient was applied to evaluate the internal consistency of the instrument. The value obtained for the GAD-7 test was ω = .91.

We analyzed the factor structure, and the reliability level of the GAD-7 test to detect GAD symptoms, considering the concepts of gender and country invariance, in a large sample of the surveyed population from LAC.

Factor analysis revealed that the GAD-7 has a unidimensional structure, explaining 70% of the variance and demonstrating adequate fit indices (RMSEA = 0.062, CFI = 0.997, TLI = 0.995, SRMR = 0.017). This confirms that the items of the instrument reflect a single factor of generalized anxiety. This finding aligns with international literature, which has consistently shown in various national contexts that the GAD-7 reliably measures a single factor associated with disorder symptoms (13, 34). Furthermore, multiple global studies have validated its reliability, establishing it as a key tool for both clinical practice and research (17, 20, 35, 36).

These results indicate that the GAD-7 can identify symptoms of generalized anxiety without the need to divide the items into subscales. The consistency of its factorial structure across different countries supports the instrument’s validity and reinforces its applicability at an international level, offering a standardized approach to detecting the disorder. This is particularly relevant in Latin America and the Caribbean, where reliable, accurate, and affordable tools are needed for the consistent detection of generalized anxiety.

Secondly, we demonstrated the factorial invariance of the GAD-7 considering participants’ gender and country of residence. The results indicate that the GAD-7 maintains equivalence at all levels (configural, metric, scalar, and strict), both between men and women and across the different countries evaluated. These findings are particularly significant, given that studies analyzing the stability of the instrument by gender and country remain limited (36); although the invariance of the instrument has been confirmed in other contexts (37–39).

In this context, the available evidence has demonstrated the usefulness of the GAD-7 in various settings across Latin America. The instrument has been used to identify symptoms of generalized anxiety in populations receiving healthcare services (14, 40, 41), university students (42–44), and the general population (36, 45, 46).

Finally, our study confirmed the high reliability of the GAD-7, as evidenced by an Omega coefficient of 0.91, which ensures the instrument’s ability to consistently detect GAD symptoms. Specifically, a value greater than 0.90 reflects a high degree of homogeneity among the test items, ensuring that each item contributes equally to measuring the construct’s structure. These findings align with previous studies conducted in various countries, which have also reported high internal consistency indices for the GAD-7 (16, 47–50).

These findings are particularly relevant in the Latin American context, where access to mental health services is limited. In this scenario, the GAD-7 stands out for its reliability and stability in measurement, exceeding the recommended threshold for evaluations in clinical practice. This makes it a fast and accurate tool that facilitates early diagnosis and timely interventions for the detection of GAD.

Although this study presents adequate results, it has some limitations. First, construct validity was not assessed; however, the analyses showed that the GAD-7 has adequate internal consistency and a factorial structure invariant across gender and country. Second, the cross-sectional design limits the evaluation of changes in generalized anxiety levels over time. Future longitudinal studies would be valuable, particularly in a post-pandemic context. Third, no information was collected on premorbid state or prior mental health conditions, making it difficult to conduct more detailed causal analyses, such as case-control studies. Fourth, although the sample included several countries from Latin America and the Caribbean (LAC), it lacked representation of minority subgroups, such as Indigenous communities, rural areas, and economically vulnerable populations. This limits the understanding of the cultural applicability of the GAD-7 and its cultural equivalence, which could be improved by expanding the sample (44, 45). Fifth, factorial invariance by age was not analyzed, a relevant aspect since anxiety symptoms may vary across age groups. Finally, the use of self-reported data poses risks of response bias and limits the generalization of results. The absence of clinical variables and diagnostic interviews restricts clinical validation. Advanced methodologies, such as Differential Item Functioning (DIF) analysis, would be necessary to address potential cultural biases and improve accuracy in diverse populations.

Currently, the scale validation is based on self-reported data, which is a widely used approach in psychological and social sciences research. However, future studies should incorporate clinical validation using criterion-related measures (51), such as structured interviews or comparisons with established diagnostic tools. The inclusion of external validation criteria would ensure that the scores obtained through the scale are aligned with clinically recognized constructs (52), thereby increasing the scale’s applicability in both research and clinical settings.

Future research should aim to validate the scale using clinical criteria, such as structured interviews and comparisons with diagnostic tools, to strengthen the interpretative validity of the results. The inclusion of clinical background information, such as medication use and comorbidity, would provide a more comprehensive understanding of the population. Additionally, employing Item Response Theory (IRT) models, such as the Rasch model (53, 54), and conducting cross-group comparisons by gender and country would enhance the generalizability and cultural sensitivity of the scale. Finally, addressing self-selection bias through random or stratified sampling techniques would reduce ambiguity concerning the population represented in the study and improve the inferential validity of the findings.

Considering these limitations, we can conclude that the GAD-7 maintains a stable factorial structure across both men and women, as well as among different countries in LAC. This provides a solid empirical foundation for the use of the GAD-7 in clinical and epidemiological research within the region and across diverse contexts. Additionally, it facilitates the early detection of anxiety and supports the implementation of mental health policies that address the specific needs of the region.